Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback